Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Roundtable on Personalized Therapy Innovation in Rare Disease: Focus on Public Policy
Track : Track 08:Regulatory Affairs and Submissions
Program Code: 133
Date: Monday, June 24, 2013
Time: 2:30 PM to 4:00 PM  EST
Location: 253A
CHAIR :
 Jeffrey N. Stuart, PhD,RAC (SCHNON), Director, Regulatory Affairs, Novartis Pharmaceuticals Corporation, United States
SPEAKER (S):
 Federico Manuel Goodsaid, PhD (SPKNON), Vice President, Strategic Regulatory Intelligence, Vertex Pharmaceuticals, United States
 Mark Trusheim, (SPKNON), Executive in Residence and Visiting Scientist, Massachusetts Institute of Technology, Sloan School of Management, United States
Russell J. Teagarden, (SPKSUP), Senior Vice President, Medical and Scientific Affairs, National Organization For Rare Disorders (NORD), United States
Description
Orphan product developers face unique challenges that multiply when combined with the need for co-registered diagnostic devices. This forum will discuss the latest policy trends impacting personalized orphan products and patient access.

Session Recording
(Code: 133)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON2 Comp Access: Monday Online Access Package - June 24, 2013
Handout Online
(Code: 133)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON2 Comp Access: Monday Online Access Package - June 24, 2013
Roundtable on Personalized Therapy Innovation in Rare Disease: Focus on Public Policy